TLDR:
- Hims & Hers Health has added Eli Lilly’s Zepbound and generic liraglutide to its weight loss offerings
- Zepbound will cost $1,899 per month on the platform, compared to $349 for self-paying customers on LillyDirect
- The company expects its weight loss offerings to generate at least $725 million in revenue in 2025
- HIMS stock closed up 5.1% to $31.05 on the news but retreated 2.3% in after-hours trading
- Eli Lilly clarified it has “no affiliation” with Hims & Hers Health
Telehealth platform Hims & Hers Health (HIMS) announced on Tuesday that it has expanded its weight loss treatment options by adding Eli Lilly’s Zepbound and generic liraglutide to its platform.
The company stated that these additions aim to provide customers with more choices to suit their individual needs.
Tirzepatide, sold under the brand name Zepbound by Eli Lilly, joins other popular weight loss medications already available on the platform.
Hims & Hers also offers medications such as Novo Nordisk’s Ozempic and Wegovy, priced at $1,799 and $1,999 per month respectively.
According to the company’s website, Zepbound will be available to its customers for $1,899 per month.
In contrast, Eli Lilly stated that patients with insurance coverage for Zepbound may pay as little as $25. Self-paying customers can access it starting at $349 per month through LillyDirect.
Eli Lilly was quick to clarify that it has “no affiliation” with the San Francisco-based telehealth company.
Growing Weight Loss Market
The move comes as Hims & Hers continues to capitalize on the booming market for GLP-1 medications, which have surged in popularity for weight management.
GLP-1 medications like Zepbound, Mounjaro, and liraglutide have become highly sought after as effective weight loss solutions.
Hims & Hers first entered the weight loss market in late 2023 with an oral-based program. This offering quickly scaled to over $100 million in revenue run rate within about seven months.
The company then launched its GLP-1 offering in the second quarter of 2024, which generated approximately $225 million in incremental revenue that year.
Chief Executive Andrew Dudum previously noted that 200,000 customers joined the platform within a year specifically for weight loss solutions.
“Consumers are very motivated to lose weight and have a holistic platform to do so,” Chief Financial Officer Oluyemi Okupe remarked after the company reported strong fourth-quarter results.
Financial Impact and Future Plans
The obesity market is central to Hims & Hers’ business strategy, with the company projecting significant revenue from this segment.
Hims & Hers expects its weight loss specialties to contribute at least $725 million in revenue in 2025, excluding any contributions from compounded semaglutide.
This projection is substantial considering the company reported nearly $1.5 billion in total revenue last year from more than 2 million customers.
Dr. Craig Primack, Senior Vice President of Weight Loss at Hims & Hers, stated in a blog post: “As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic, personalized experience.”
The company emphasized its “long-term commitment to build the most comprehensive and personalized digital health platform for weight loss and beyond.”
Hims & Hers has navigated challenges in the GLP-1 market, including supply shortages and regulatory changes.
In May, the company began prescribing compounded semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy.
However, the FDA announced in February that the shortage of semaglutide injection products had been resolved, limiting the company’s ability to offer compounded versions.
The company is actively lobbying for continued access to compounded medications, encouraging users to urge Congress and the FDA to preserve access to these treatments.
Market Response
Investors responded positively to the news, with HIMS stock closing up 5.1% at $31.05 on Tuesday. The stock reached an intraday high of $33.70.
However, shares retreated 2.3% to $30.33 in after-hours trading.
Year-to-date, Hims & Hers shares have gained approximately 27% in 2025, following a remarkable 172% surge in 2024.
The company’s latest move to expand its weight loss offerings appears aligned with its strategy to capture a larger share of the rapidly growing obesity treatment market.
Liraglutide, which requires daily injections and may be less effective than other GLP-1 medications, will be available at a lower price point of $299 per month.
According to the company, this particular pricing strategy aims to provide more affordable options for users seeking weight loss solutions.
Stay Ahead of the Market with Benzinga Pro!
Want to trade like a pro? Benzinga Pro gives you the edge you need in today's fast-paced markets. Get real-time news, exclusive insights, and powerful tools trusted by professional traders:
- Breaking market-moving stories before they hit mainstream media
- Live audio squawk for hands-free market updates
- Advanced stock scanner to spot promising trades
- Expert trade ideas and on-demand support
